An observational study in Breast Cancers and Ovarian Cancers, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Institut Paoli-Calmettes · Observational
Jiao Y, Lesueur F, Azencott CA, Laurent M, Mebirouk N, Laborde L, Beauvallet J, Dondon MG, Eon-Marchais S, Lauge A; GEMO Study Collaborators; GENEPSO Study Col…PubMed 34325649 ↗; 9 more
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Breast Neoplasms by Institut Paoli-Calmettes — 6 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Institut Paoli-Calmettes.
Among the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes, this one is the only one that started in 1999, is one of 5 observational ones, and was the 17th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →6 of the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes are open now, in 1 country. Recruiting first, the newest first:
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Women only
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Women only
Institut Paoli-Calmettes · Sites in France
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Women only
Institut Paoli-Calmettes
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3
First in 1995; this study’s year is marked. 1 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 72 across the 19 interventional studies, 5,000 across the 5 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Paoli-Calmettes is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
3 of the studies in Breast Neoplasms by Institut Paoli-Calmettes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05143970Institut Paoli-CalmettesA Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | 2027-03 |
| NCT05986071Institut Paoli-CalmettesI/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers | 2027-04-01 |
| NCT05519670Institut Paoli-CalmettesA Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
women and men with a BRCA1 or BRCA2 mutation
Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.
Exclusion Criteria:
subjects carrying a BRCA gene mutation
Other: Questionnaires
standardized data collection and 10-year prospective follow-up
Incidence of breast and / or ovarian cancer during subject lifetime
risk that a subject with a mutation develops breast and / or ovarian cancer during his lifetime, assessed by epidemiologic questionnaires (carcinologic events).
Time frame: 10 years
Plan to share: No
Started Oct 1999 (actual). Primary completion is estimated for Oct 2028, 348 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 348 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Jiao Y, Lesueur F, Azencott CA, Laurent M, Mebirouk N, Laborde L, Beauvallet J, Dondon MG, Eon-Marchais S, Lauge A; GEMO Study Collaborators; GENEPSO Study Col…PubMed 34325649 ↗; 9 more
Jiao Y, Lesueur F, Azencott CA, Laurent M, Mebirouk N, Laborde L, Beauvallet J, Dondon MG, Eon-Marchais S, Lauge A; GEMO Study Collaborators; GENEPSO Study Col…PubMed 34325649 ↗; 9 more
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.